Evelina Mocci

TL;DR: Surveillance of CDNK2A mutation carriers is relatively successful, detecting most PDACs at a resectable stage, and the benefit of surveillance in families with FPC is less evident.

TL;DR: This study identifies new loci associated with pancreatic cancer risk in North America, Central Europe and Australia and replicated previously reported associations at 9q34.2 (ABO), 13q22.1 (KLF5), 5p15.33 (TERT and CLPTM1) and 13q12.4 (NR5A2), a region with previous suggestive evidence in Han Chinese.

TL;DR: The largest pancreatic cancer GWAS to date, including 9040 patients and 12,496 controls of European ancestry from the PANScan and the Pancreatic Cancer Case Control Consortium (PanC4), was performed in this paper.

TL;DR: In this paper, the authors performed imputation based on 1000 Genomes (1000G) Project data and association analysis using 5,107 case and 8,845 control subjects from 27 cohort and case-control studies that participated in the PanScan I-III GWAS.

TL;DR: Germline mutations in BRCA1 and BRCa2 are associated with an increased risk of pancreatic cancer, pointing to the existence of other genetic factors that increase the risk of both pancreatic cancers and breast cancer.